NS IDIQ: operations and technical support (OTS) for the frederick national laboratory for cancer research (fnlcr), a federally funded research and development center (ffrdc)
Ended Indefinite Delivery Contract Awarded Last action
- Contract number
- HHSN261201500003I
- Awardee
-
Leidos Biomedical Research Inc. UEI HV8BH9BPG8Y9 Part of Leidos Holdings, Inc.
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Task orders
- 85 $1,227,665,566 obligated
Award facts
- Opportunity
-
- N01CO5240180 Solicitation number
- Operations and Technical Support for the Frederick National Laboratory for Cancer Research (FLNCR), a Federally Funded Research and Development Center (FFRDC) Award Notice · Posted Apr 27, 2015
- Combined order value
-
- $1,252,614,087 Current, with exercised options
- $1,280,620,501 Potential, with all options
- Last date to order 100% complete
- IDV ceiling 83% used
- $1,486,959,616.00
- Maximum order
- $1,486,959,616.00
- Award type
- Single award
- Who can order
- Only the awarding agency
- NAICS code
- 561210 Facilities Support Services
- Set-aside
- No set-aside
- Competition
- Not Competed · 1 offer Only One Source
- Pricing
- Order Dependent (IDV only)
Award details come from SAM.gov/FPDS.
About this IDV
The National Cancer Institute awarded a single-award Indefinite Delivery Contract valued at $1.487 billion to Leidos Biomedical Research Inc., a subsidiary of Leidos Holdings, Inc., effective September 26, 2015, through August 30, 2019. This contract establishes Leidos Biomedical Research as the Federally Funded Research and Development Center (FFRDC) operator for the Frederick National Laboratory for Cancer Research, providing comprehensive Operations and Technical Support across the NCI's research enterprise. The contract encompasses facilities operations and maintenance, biomedical research and development, manufacturing of therapeutic agents and vaccines, clinical trials management, specialized laboratory testing and analysis, and infrastructure modernization at the Fort Detrick, Maryland campus. The FFRDC structure enables the NCI to procure flexible, integrated research support services without conducting individual competitive solicitations for discrete projects, establishing Leidos Biomedical Research as the primary provider of mission-critical research infrastructure and scientific capabilities.
The delivery orders issued under this IDV demonstrate the breadth of services delivered, spanning cancer research initiatives including patient-derived xenograft development, immunotherapy product development, tumor characterization analysis, and precision oncology laboratory networks; infectious disease research including Ebola virus studies, HIV therapeutic antibody development, vaccine platform advancement for influenza and Zika, and malaria vaccine development; facilities infrastructure projects including building refurbishment, mechanical system upgrades, and liquid nitrogen distribution expansion; and advanced research capabilities including genomic sequencing, multi-omics analysis, biomarker assay development, and data commons expansion. Delivery orders totaling hundreds of millions of dollars have been issued to Leidos Biomedical Research through this vehicle, with individual task orders ranging from approximately $750,000 to $67 million, supporting the NCI's mission in cancer research while also serving the broader National Institutes of Health enterprise through collaborative efforts with institutes including the National Institute of Allergy and Infectious Diseases and the National Center for Advancing Translational Sciences.
Task orders
Show 40 more
Latest 50 of 85 listed here. See the rest on GovTribe.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Original award | $0 |
Show all 19
Subawards
| Subcontractor | Amount | Awarded |
|---|---|---|
| Mitchell Group, Inc. (The) | $8,604,378 | |
| Mitchell Group, Inc. (The) | $7,855,239 | |
| Mitchell Group, Inc. (The) | $987,336 | |
| Mitchell Group, Inc. (The) | $987,336 | |
| Cold Spring Harbor Laboratory | $7,805,839 |
Quick answers
Who was awarded contract HHSN261201500003I?
HHSN261201500003I was awarded to Leidos Biomedical Research Inc. by National Cancer Institute (National Institutes of Health) on September 26, 2015.
How much is contract HHSN261201500003I worth?
Orders under HHSN261201500003I have obligated $1,227,665,566. Their combined current value, with exercised options, is $1,252,614,087. Their combined potential value, with all options, is $1,280,620,501. HHSN261201500003I's own ceiling is $1,486,959,616. A single order can be worth up to $1,486,959,616.
How many orders have been placed under contract HHSN261201500003I?
85 orders have been placed under HHSN261201500003I, the latest on August 2, 2019.
Who can order from contract HHSN261201500003I?
HHSN261201500003I is a single award indefinite delivery contract. Only the awarding agency can place orders on it.
Was contract HHSN261201500003I competed?
The extent of competition for HHSN261201500003I was not competed. The government received 1 offer.
On GovTribe
See this IDV's full record
- Every order and transaction
- The awardee's other awards and teaming partners
- Similar IDVs and recompete opportunities
- Ask GovTribe AI about this IDV